Related Experiment Video
Updated: May 2, 2026

CRISPR/Cas9 Gene Editing of Hematopoietic Stem and Progenitor Cells for Gene Therapy Applications
Published on: August 9, 2022
Gene therapy for hemoglobinopathies: the state of the field and the future
Shanmuganathan Chandrakasan1, Punam Malik2
1Division of Hematology, Oncology and Bone Marrow Transplant, Cancer and Blood Disease Institute (CBDI), Cincinnati Children's Hospital Medical Center (CCHMC), 3333 Burnet Avenue, Cincinnati, OH 45229, USA.
Abstract:
After nearly two decades of struggle, gene therapy for hemoglobinopathies using vectors carrying β or γ-globin gene has finally reached the clinical doorsteps. This was made possible by advances made in our understanding of critical regulatory elements required for high level of globin gene expression and improved gene transfer vectors and methodologies. Development of gene editing technologies and reprogramming somatic cells for regenerative medicine holds the promise of genetic correction of hemoglobinopathies in the future. This article will review the state of the field and the upcoming technologies that will allow genetic therapeutic correction of hemoglobinopathies.
More Related Videos
Related Concept Videos
Gene Therapy
Gene Therapy
Microorganisms in Medicine and Therapeutics
Role of Hematopoietic Growth Factors
Thrombopoietin (TPO), mainly released by the liver,...
Gene Families
Occasionally these regions can be adapted to take on new roles within the organism, becoming novel genes...
Hemoglobin
When all four heme groups are bound to oxygen, the resulting molecule is called oxyhemoglobin. As a result, arterial blood...

